ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
37 hedge funds and large institutions have $8.67M invested in ImmunoCellular Therapeutics, Ltd. in 2013 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 14 reducing their positions, and 19 closing their positions.
14% less capital invested
Capital invested by funds: $10.1M → $8.67M (-$1.46M)
24% less funds holding
Funds holding: 49 → 37 (-12)
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
71% less call options, than puts
Call options by funds: $724K | Put options by funds: $2.52M
79% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$834K |
| 2 |
HCM
Highbridge Capital Management
New York
|
+$340K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$299K |
| 4 |
BG
BlackRock Group
London,
United Kingdom
|
+$98.2K |
| 5 |
IFS
Ifrah Financial Services
Little Rock,
Arkansas
|
+$78.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$1.15M |
| 2 |
Goldman Sachs
New York
|
-$688K |
| 3 |
Barclays
London,
United Kingdom
|
-$453K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$427K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$422K |
IMUC Hedge Fund Activity: Q3 2013 in Review
37 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q3 2013, worth a combined $8.67M — down 14% from $10.1M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of IMUC and 8 opened new positions — a net loss of 11 holders — while 14 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $834K. The largest seller was Northern Trust, cutting an estimated $1.15M.
- 37 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q3 2013, down from 49 in Q2 2013.
- Funds reported $8.67M of ImmunoCellular Therapeutics, Ltd. stock for Q3 2013, down 14% quarter-over-quarter.
- 8 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q3 2013 and 19 closed out, a net change of -11 holders.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q3 2013 was Vanguard Group, an estimated $834K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q3 2013 was Northern Trust, an estimated $1.15M sold.
Based on aggregated 13F filings for Q3 2013.